Patient access stories

Oct 23, 2026

Real-world study confirms Lu-PSMA-617 benefits for metastatic prostate cancer patients

Results from France's early-access program demonstrate that PSMA-targeted radiopharmaceutical therapy Lu-PSMA-617 is safe and effective for patients with metastatic castration-resistant prostate cancer in routine clinical practice, confirming findings from controlled trials.

Oct 23, 20264 sources

Top claims

▪Prostate cancer mortality after four years was 5% among DASL-HiCaP trial participants treated with darolutamide compared to 14% among participants given a placebo.
▪Johnson & Johnson presented early-stage clinical trial data showing its experimental oral prostate cancer drug JNJ-6143 produced PSA reductions of at least 50% in 77% of evaluable patients at a 50-mg dose.
▪In the 1,106-patient DASL-HiCaP trial, 95% of patients receiving darolutamide had not developed metastatic prostate cancer after four years compared to 88% of patients receiving a placebo.

Subtopics

Cancer & Oncology1 Cancer research1 Cancer treatment1 Cancer Treatment & Therapies1 Oncology1 Real world evidence1 Targeted cancer therapy1

Related timelines